The importance of non-HDL cholesterol reporting in lipid management

Michael Blaha, Roger S Blumenthal, Eliot A. Brinton, Terry A. Jacobson

Research output: Contribution to journalArticle

Abstract

Plasma levels of lipids and lipoproteins are essential to the management of lipid disorders by generalists and by practitioners of the emerging specialty of clinical lipidology. The routine lipid panel consists of total cholesterol, low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and triglycerides. Several additional lipid parameters are emerging as potentially valuable adjuncts to the standard panel, including measurements of apolipoproteins and LDL particle size and concentration, but most of these serve mainly as research tools at present. One major exception is non-HDL-C, which is readily available for routine clinical use. This review outlines some of the numerous research studies that clearly establish the clinical utility and even preeminence of non-HDL-C as a comprehensive measure of atherogenic lipoproteins. Non-HDL-C was highlighted as a key secondary goal of therapy several years ago in the National Cholesterol Education Program Adult Treatment Panel III national lipid treatment guidelines and recently was further emphasized as a major goal of therapy in the consensus guidelines for lipoprotein management in patients with cardiometabolic risk from the American Diabetes Association and the American College of Cardiology. Non-HDL-C is superior to LDL-C for the prediction of cardiovascular events and has many other compelling advantages over LDL-C and other traditional lipid parameters. Importantly, it can be calculated directly from values in routine lipid panels, at no added expense. It is our opinion that non-HDL-C should be reported on all routine lipid profiles and used regularly in the management of dyslipidemia for optimal prevention of atherosclerosis and cardiovascular disease.

Original languageEnglish (US)
Pages (from-to)267-273
Number of pages7
JournalJournal of Clinical Lipidology
Volume2
Issue number4
DOIs
StatePublished - Aug 2008

Fingerprint

Cholesterol
Lipids
LDL Cholesterol
Lipoproteins
Guidelines
Apolipoproteins
Therapeutics
Dyslipidemias
Research
Particle Size
HDL Cholesterol
Atherosclerosis
Cardiovascular Diseases
lipoprotein cholesterol
Education

Keywords

  • Lipid management
  • Lipid panel reporting
  • Lipidology
  • Lipoproteins
  • Non-HDL-C

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Endocrinology, Diabetes and Metabolism
  • Internal Medicine
  • Nutrition and Dietetics

Cite this

The importance of non-HDL cholesterol reporting in lipid management. / Blaha, Michael; Blumenthal, Roger S; Brinton, Eliot A.; Jacobson, Terry A.

In: Journal of Clinical Lipidology, Vol. 2, No. 4, 08.2008, p. 267-273.

Research output: Contribution to journalArticle

@article{df8d56c1f0a5404d91bdb52b853c898d,
title = "The importance of non-HDL cholesterol reporting in lipid management",
abstract = "Plasma levels of lipids and lipoproteins are essential to the management of lipid disorders by generalists and by practitioners of the emerging specialty of clinical lipidology. The routine lipid panel consists of total cholesterol, low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and triglycerides. Several additional lipid parameters are emerging as potentially valuable adjuncts to the standard panel, including measurements of apolipoproteins and LDL particle size and concentration, but most of these serve mainly as research tools at present. One major exception is non-HDL-C, which is readily available for routine clinical use. This review outlines some of the numerous research studies that clearly establish the clinical utility and even preeminence of non-HDL-C as a comprehensive measure of atherogenic lipoproteins. Non-HDL-C was highlighted as a key secondary goal of therapy several years ago in the National Cholesterol Education Program Adult Treatment Panel III national lipid treatment guidelines and recently was further emphasized as a major goal of therapy in the consensus guidelines for lipoprotein management in patients with cardiometabolic risk from the American Diabetes Association and the American College of Cardiology. Non-HDL-C is superior to LDL-C for the prediction of cardiovascular events and has many other compelling advantages over LDL-C and other traditional lipid parameters. Importantly, it can be calculated directly from values in routine lipid panels, at no added expense. It is our opinion that non-HDL-C should be reported on all routine lipid profiles and used regularly in the management of dyslipidemia for optimal prevention of atherosclerosis and cardiovascular disease.",
keywords = "Lipid management, Lipid panel reporting, Lipidology, Lipoproteins, Non-HDL-C",
author = "Michael Blaha and Blumenthal, {Roger S} and Brinton, {Eliot A.} and Jacobson, {Terry A.}",
year = "2008",
month = "8",
doi = "10.1016/j.jacl.2008.06.013",
language = "English (US)",
volume = "2",
pages = "267--273",
journal = "Journal of Clinical Lipidology",
issn = "1933-2874",
publisher = "Elsevier BV",
number = "4",

}

TY - JOUR

T1 - The importance of non-HDL cholesterol reporting in lipid management

AU - Blaha, Michael

AU - Blumenthal, Roger S

AU - Brinton, Eliot A.

AU - Jacobson, Terry A.

PY - 2008/8

Y1 - 2008/8

N2 - Plasma levels of lipids and lipoproteins are essential to the management of lipid disorders by generalists and by practitioners of the emerging specialty of clinical lipidology. The routine lipid panel consists of total cholesterol, low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and triglycerides. Several additional lipid parameters are emerging as potentially valuable adjuncts to the standard panel, including measurements of apolipoproteins and LDL particle size and concentration, but most of these serve mainly as research tools at present. One major exception is non-HDL-C, which is readily available for routine clinical use. This review outlines some of the numerous research studies that clearly establish the clinical utility and even preeminence of non-HDL-C as a comprehensive measure of atherogenic lipoproteins. Non-HDL-C was highlighted as a key secondary goal of therapy several years ago in the National Cholesterol Education Program Adult Treatment Panel III national lipid treatment guidelines and recently was further emphasized as a major goal of therapy in the consensus guidelines for lipoprotein management in patients with cardiometabolic risk from the American Diabetes Association and the American College of Cardiology. Non-HDL-C is superior to LDL-C for the prediction of cardiovascular events and has many other compelling advantages over LDL-C and other traditional lipid parameters. Importantly, it can be calculated directly from values in routine lipid panels, at no added expense. It is our opinion that non-HDL-C should be reported on all routine lipid profiles and used regularly in the management of dyslipidemia for optimal prevention of atherosclerosis and cardiovascular disease.

AB - Plasma levels of lipids and lipoproteins are essential to the management of lipid disorders by generalists and by practitioners of the emerging specialty of clinical lipidology. The routine lipid panel consists of total cholesterol, low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and triglycerides. Several additional lipid parameters are emerging as potentially valuable adjuncts to the standard panel, including measurements of apolipoproteins and LDL particle size and concentration, but most of these serve mainly as research tools at present. One major exception is non-HDL-C, which is readily available for routine clinical use. This review outlines some of the numerous research studies that clearly establish the clinical utility and even preeminence of non-HDL-C as a comprehensive measure of atherogenic lipoproteins. Non-HDL-C was highlighted as a key secondary goal of therapy several years ago in the National Cholesterol Education Program Adult Treatment Panel III national lipid treatment guidelines and recently was further emphasized as a major goal of therapy in the consensus guidelines for lipoprotein management in patients with cardiometabolic risk from the American Diabetes Association and the American College of Cardiology. Non-HDL-C is superior to LDL-C for the prediction of cardiovascular events and has many other compelling advantages over LDL-C and other traditional lipid parameters. Importantly, it can be calculated directly from values in routine lipid panels, at no added expense. It is our opinion that non-HDL-C should be reported on all routine lipid profiles and used regularly in the management of dyslipidemia for optimal prevention of atherosclerosis and cardiovascular disease.

KW - Lipid management

KW - Lipid panel reporting

KW - Lipidology

KW - Lipoproteins

KW - Non-HDL-C

UR - http://www.scopus.com/inward/record.url?scp=48549093490&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=48549093490&partnerID=8YFLogxK

U2 - 10.1016/j.jacl.2008.06.013

DO - 10.1016/j.jacl.2008.06.013

M3 - Article

VL - 2

SP - 267

EP - 273

JO - Journal of Clinical Lipidology

JF - Journal of Clinical Lipidology

SN - 1933-2874

IS - 4

ER -